Michael McCaughan (left) and Tom O’Donnell (right) speak during a Feb. 11 “Washington Update” keynote address at the 340B Coalition Winter Conference in San Diego.
Major Congressional 340B Action Unlikely in 2026, but Trump Administration Policies Could Still Affect Program, Health Policy Experts Say
Major federal 340B legislation is unlikely to move through Congress in 2026—but a series of White House drug pricing initiatives [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
